Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Review of 46 CAR T-cell treatments to 43 patients found that 51% of treatments had a .3 year duration of response and the mean event free survival was 55 months. Long term effects were rare except for B-cell depletion and hypogammaglobulinemia.

Journal of Clinical Oncology